Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) toinvestigate the optimal duration of preoperative endocrine therapy

Breast

Volumn 22, Issue 3, 2013, Pages 263-267

  Hojo, Takashi ^a   Kinoshita, Takayuki ^a   Imoto, Shigeru ^b   Shimizu, Chikako ^a   Isaka, Hirotsugu ^b   Ito, Hiroki ^b   Imi, Kentaro ^b   Wada, Noriaki ^c   Ando, Masashi ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KYORIN UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Breast cancer; Neo adjuvant endocrine therapy; Optimal treatment duration time

Indexed keywords

ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL EXAMINATION; CLINICAL SUPERVISION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUMOR INVASION; UNSPECIFIED SIDE EFFECT;

EID: 84877134909     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.03.002     Document Type: Article

References (18)

1. Wolmark N., Wang J., Mamounas E., Byant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. JNatl Cancer Inst Monogr 2001, 96-102.
2. Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Walsh G., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. JClin Oncol 2005, 23:5108-5116.
3. Cataliotti L., Buzdar A.U., Noguchi S., Bines J., Takatsuka Y., Oliveira C.T., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006, 106:2095-2103.
4. Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Borgs M., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12:1527-1532.
5. Krainick U., Astner A., Jonat W., Wallwiener D. Phase 11 study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative (GENARI) 2003, San Antonio, [Abstract 239].
6. Tubiana-Hulin M., Becette V., Bieche I., Mauriac L., Romieu G., Bibeau F., et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res 2007, 27:2689-2696.
7. Gil Gil M.J., Barnadas A., Cirera L., Tusquets I., Munoz M., Margeli M., et al. Primary hormonal therapy with exemestane in patients with breast tumours >3cm in diameter: results of a Spanish multicenter phase II trial. Proc Am Soc Clin Oncol 2004, 23:14S. (Abs603).
8. Mustacchi G., Mansutti M., Barni S., Cazzaniga M.E., Farris A., Dellach C., et al. Exemestane(EXE)as primary treatment in hormonosensible early breast cancer of the elderly :preliminary results of a phase II multicenter open Italian study. Proc Am Soc Clin Oncol 2006, 24:18S. (Abs10689).
9. RECIST.
10. Kurosumi M., Akashi-Tanaka S., Akiyama F., Komoike, Mukai H., Tsuda H., et al. Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer 2008, 15:5-7.
11. Shimon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials; 10: 1-10.
12. Colleoni M., Gelber S., Coates A.S., Castiglione-Gertsch M., Gelber R.D., Goldhirsch A., et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. JClin Oncol 2001, 19:4141-4149.
13. Gianni L., Baselga J., Eiermann W., Guillem Porta V., Semiglazov V., Bonadonna G., et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005, 11:8715-8721.
14. Tan S.M., Cheung K.L., Willsher P.C., Blamey R.W., Chan S.Y., Robertson J.F., et al. Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 2001, 37:2331-2338.
15. Robertson J.F., Ellis I.O., Elston C.W., Blamey R.W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992, 28A:908-910.
16. Mustacchi G., Ceccherini R., Milani S., Pluchinotta A., De Matteis A., Sasso F., et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003, 14:414-420.
17. Krainick-Strobel U.E., Lichtenegger W., Wallwiener D., Tulusan A.H., Janicke F., Paepke S., et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 2008, 8:62.
18. Llombart-Cussac A., Guerrero A., Galán A., Carañana V., Buch E., Guillem Porta V., et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol 2012, 14(2).